Giredestrant (Wilserdly) FDA Approval

✓ Medically reviewed | Published: | Evidence level: 1A
The FDA has approved Genentech's giredestrant (Wilserdly), a next-generation oral selective estrogen receptor degrader, for ER-positive, ESR1-mutated advanced breast cancer. The approval adds to a small but growing class of oral endocrine therapies aimed at tumors that have developed resistance to standard hormone treatment.
📅 Published:
✓ Reviewed by iMedic Medical Editorial Team
📄 Oncology

Quick Facts

Drug Class
Oral SERD
Target Population
ER+, ESR1-mutated advanced
Developer
Genentech (Roche)
Key Biomarker
ESR1 mutation

What is giredestrant and how does it work in breast cancer?

Quick answer: Giredestrant is an oral selective estrogen receptor degrader that blocks the estrogen receptor and promotes its breakdown, cutting off a main growth signal in hormone receptor-positive breast cancer.

Most breast cancers are estrogen receptor (ER)-positive, meaning tumor cells rely on estrogen signaling to grow. Endocrine therapy, including aromatase inhibitors and fulvestrant, has long been the backbone of treatment. Selective estrogen receptor degraders (SERDs) bind the receptor and mark it for destruction, reducing the amount of receptor available to drive tumor growth.

Fulvestrant, the first SERD, must be given by intramuscular injection and may not reach full receptor blockade in every patient. Oral SERDs such as giredestrant were designed to deliver more complete receptor inhibition with a simpler route of administration. The FDA's decision, as reported by Genentech, covers advanced disease with ESR1 mutations, a specific setting where these drugs have shown the clearest benefit.

Why do ESR1 mutations matter for treatment choice?

Quick answer: ESR1 mutations keep the estrogen receptor active even when estrogen is low, which is a common way tumors become resistant to aromatase inhibitors.

Mutations in the ESR1 gene, which encodes the estrogen receptor alpha, often emerge after prolonged aromatase inhibitor therapy. They allow the receptor to signal without estrogen, so tumors can keep growing despite treatment that lowers estrogen levels. Research suggests these mutations appear in a substantial minority of patients with metastatic ER-positive disease after endocrine therapy, and they are typically detected through tumor tissue or a blood-based liquid biopsy.

Elacestrant (Orserdu) was approved by the FDA in 2023 as the first oral SERD for ER-positive, HER2-negative, ESR1-mutated advanced breast cancer, which established ESR1 testing as a routine step in the metastatic setting. The giredestrant approval reinforces that approach. Patients and oncologists should discuss repeat biomarker testing at progression, since a tumor's mutation profile can change over time.

What should patients ask their oncologist about oral SERDs?

Quick answer: Patients should ask whether ESR1 testing has been done, how the drug compares with other options, and what side effects and monitoring to expect.

Useful questions include whether a recent liquid biopsy or tissue test has checked for ESR1 mutations, where an oral SERD fits relative to combination regimens such as CDK4/6 inhibitors or everolimus-based therapy, and how long benefit is expected to last. Giredestrant has been studied both alone and in combination with other agents, and the label's specific indication determines how it is used.

Side effects of endocrine therapies commonly include fatigue, joint or musculoskeletal symptoms, nausea and hot flashes, but each drug has its own profile. Patients should review the full prescribing information with their care team. Cost and insurance coverage for newly approved oral oncology drugs can also vary, so early conversations with a pharmacist or financial counselor can help.

Frequently Asked Questions

No. Giredestrant is an oral hormonal (endocrine) therapy that targets the estrogen receptor. It works differently from chemotherapy, although side effects and monitoring still need medical supervision.

Based on the FDA announcement, it is indicated for ER-positive, ESR1-mutated advanced breast cancer. Eligibility depends on confirmed ESR1 mutation status and the exact label wording, which an oncologist can interpret for an individual patient.

ESR1 status is determined by testing tumor tissue or, more commonly at progression, a blood-based liquid biopsy. Ask your oncologist whether recent testing has been done.

References

  1. Business Wire. FDA Approves Genentech's WILSERDLY (Giredestrant), a Next-Generation Oral SERD, for ER-Positive, ESR1-Mutated Advanced Breast Cancer. November 2026.
  2. U.S. Food and Drug Administration. FDA approves elacestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. January 2023.
  3. National Cancer Institute. Breast Cancer Treatment (PDQ) - Health Professional Version.